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Abstract
Based on findings in the article “Redesigning the designer drug ecstasy: non-
psychoactive MDMA analogues exhibiting Burkitt’s lymphoma” (J. Gordon et al., 
2010) we wanted to study how MDMA worked, and how it can be used as a treatment 
for cancer. The study was made based on MDMA’s ability to kill Burkitt’s lymphoma 
cells, by stimulating serotonin release that stimulate the pro apoptotic BCL-2 proteins 
so the Burkitt’s lymphoma cells goes into apoptosis. 
Because of MDMA’s neurotoxicity and psychoactivity the study tested different 
MDMA analogues that ruled out neurotoxicity and psychoactivity. Furthermore they 
tested analogues which were more effective in killing the cancer cells, so a much 
lower dose was needed.
The report includes background knowledge about cancer, what cancer is and does and 
how different cancers are treated. It will also include background knowledge about 
MDMA, how it works and what it does. It will describe how the analogues works and 
how it is related to serotonin, BCL-2 proteins and the Burkitt’s lymphoma cells. It 
showed that there is a good opportunity that MDMA analogues in the future can be a 
substitute for treatment of some cancers. If psychoactivity and neurotoxicity can be 
ruled out, the side effects compared to chemotherapy for example, would be almost 
none.  
Introduction
According to a recent study “Redesigning the designer drug ecstasy: non-
psychoactive MDMA analogues exhibiting Burkitt's lymphoma” (J. Gordon et al., 
2010), analogues of MDMA might have a chapter of it's own in the fight against 
certain types of blood cancer.
By experimenting in vitro, using leukaemia, lymphoma and myeloma cells (J. Gordon 
et al., 2010), scientist could observe the effectiveness of MDMA against cancer cells, 
stating they have increased it's effectiveness 100-fold (J. Gordon et al., 2010).
A research at the University of Birmingham showed the potential of MDMA and anti-
depressants, as Prozac, to start apoptosis in Burkitt's lymphoma (BL) cells. (J. Gordon 
et al., 2005) But due to the neurotoxicity, the required dose to kill all cancer cells with 
MDMA would lead to fatalities (J. Gordon et al., 2010). In collaboration with the 
Western Australia University, researchers have chemically modified MDMA by 
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removing a methyl group and replacing it with various other groups. As a result of this 
chemically altering of MDMA, one variant increased it's effectiveness a 100-fold. 
That would mean that 100 times less of the MDMA-analogue is needed compared to 
MDMA to obtain the same cytotoxic effect. And in addition to that, the found 
compound had a reduced neurotoxicity (J. Gordon et al., 2010).
Professor John Gordon from Birmingham University stated, to the BBC: ”Against the 
cancers, particularly the leukaemia, the lymphoma and the myeloma, where we've 
tested these new compounds we can wipe out 100% of the cancer cells in some 
cases.” (J. Gallagher, 2010)
The alteration of the structure of MDMA made it more successful against some 
cancers, because the specific cancer cells had a larger amount of BCL-2 proteins.
It is not yet possible to administrate MDMA analogues to patients affected by cancer, 
probably only in a few decades as these analogues have only been tested in vitro. To 
be certain that a MDMA analogue can  be administrated to cancer patients, 
experiments on animals and clinical trials will be needed to test the efficiency of this 
product. As stated by Dr. David Grant, scientific director of the charity Leukemia and 
Lymphoma Research: "The prospect of being able to target blood cancer with a drug 
derived from ecstasy is a genuinely exciting proposition. Many types of lymphoma 
remain hard to treat and non-toxic drugs which are both effective and have few side 
effects are desperately needed.” (University of Birmingham 2011) MDMA analogues 
may be a solution for cancer treatment, as cancer treatment nowadays is not safe 
guarding a 100% success and carrying various side effects like for example 
Chemotherapy has. Chemotherapy consists out of the use of chemical agents to stop 
cancer cells growth and/or killing these cells. But this treatment caries various side 
effects as: low blood cell count, nausea, vomiting, hair loss, fatigue, etc. By using 
MDMA analogues, it applies to Chemotherapy treatment.
Problem Formulation
Our main focus is if MDMA analogues can be used as cancer treatment. To answer 
the question we need to know how MDMA works in general, and how it relates to 
killing the cancer cells.
MDMA is neurotoxic and psychoactive, can this be ruled out by making analogues of 
MDMA?
4
If it was possible to rule out the neurotoxicity and psychoactivity, would the 
analogues then be able to kill the cancer cells?
At the initial research it showed that a large amount of MDMA was needed to kill the 
cancer cells, can MDMA be altered so the cytotoxicity is more effective?
If MDMA analogues can be taken as a treatment for cancer, would it then have less 
side effects than other cancer treatments, like for example chemotherapy.
If so, will the side effects weigh out the side effects from chemotherapy and surgery?
Method
The project consists of literature research as it is a very recent discovery that is still 
being worked on, where the study of articles related to the subject is the main 
foundation of this report. The conclusion will be based on a discussion about the data 
gathered, leading us to an answer to our problem formulation. 
First of all we want to get an understanding of how MDMA analogues can be used as 
a treatment for cancer.  Then we will go further into how MDMA is related to the 
cancer cells, how it actually kills the cancer cells, and how it is related to serotonin 
levels and BCL-2 protein. We will discuss the effects of MDMA and other cancer 
treatments, and compare them with each other, to conclude if MDMA analogues 
would be a better treatment for cancer.
Social Relevance 
Our project is relevant to the semester theme because it's about a cheaper and better 
accessible way to cure Burkitt's lymphoma (BL) which is the most prominent cancer 
in young people. The cure usually involves heavy chemotherapy and has a 80% of 
succeeding. But not everywhere in world this kind of treatment is readily accessible 
and affordable. BL has a higher incidence in the BL belt, which stretches from west to 
east Africa near equator because of Malaria and AIDS, the last one brings 
complications with chemotherapy (WHO, 2007). Although the frequency at which BL 
occurs is only 0.005-0.020% per year. Though putting this into perspective with the 
amount of people living in the BL belt, which is more than half a million, it still is 
accountable for 25,000 - 100.000 cases a year (J. Gordon et al., 2010). 
Therefore it would be helpful for the less fortunate people that there would be a 
alternative more accessible way of curing this disease. The way to treat people would 
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be taking in a dose of the MDMA analogue, might this be intravenous or oral, and 
would be a more humane way to treat BL. As well the research gives a good future 
perspective on maybe deriving a cure for more types of cancer then just BL. 
Especially the myeloma types of cancer seem to have interesting perspective. Which 
makes it very relevant for society, since what if no one would ever have to go through 
the treatment of conventional chemotherapy with it's many sever side effects?
Background
Cancer
When in our system a uncontrolled cell growth happens, we define it as cancer, whose 
process is denominated as carcinogenesis. Cancer cells affect a determined spot 
before spreading to the surrounding tissue to get to the blood vessels, using the 
vessels as a conduit to spread.  
Genes and chromosomes affected by cancer will have their “program” changed due to 
a disorganization caused by cancer. It has been often observed an unusual and 
undifferentiated pattern on cancer cells, described as a lost of functionality, failing to 
fully develop the characteristics and proper activities of mature cells. Remarkably, 
metastatic cancer cells gain new functions, gaining characteristics unrelated to the 
normal sedentary cell type. (P. Dash, 2007)
The Cell Cycle
The cell cycle begins when a cell (the parent 
cell) divides into two cells (daughter cells), and 
ends when the daughter cells divide and also 
become parent cells. It is clearly seen under a 
microscope, and described in illustration 1. The 
mitotic phase, also called the M phase consists 
of two events, mitosis which is the division of 
the nucleus, and cytokinesis which is the 
division of the cytoplasm. At Gap 1, also called 
G1 phase, the cell grows and the cell prepares for DNA synthesis and production of 
histones. The time the G1 phase lasts, is variable. Growing mammalian cells can 
spend 8-10 hours in the G1 phase, but a cellular decision can cause the cell to enter 
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Illustration 1: Cell cycle
the G0 state, which will stop further cell growth. After the G1 phase, the cell is 
prepared to go into S-phase. Here the DNA replication takes place by condensation of 
the chromatin, which leaves two copies of each chromosome attached at the 
centromere, this is called sister chromatids. Then the cell goes into Gap 2, also called 
the G2 phase. In this phase the cell prepares for division. The nuclear envelope 
fragments and the microtubules of the mitotic spindle separates the sister chromatids 
and places them in each end of the cell. This phase is usually shorter than G1, and 
normally takes 4-6 hours. Cytokinesis and reformation of the nuclear membranes 
completes the cell division, and the cycle repeats. (W. M. Becker et al., 2008).
Cell Death: Necrosis vs. Apoptosis
Most eukaryotic cells are genetically programmed for cell death, or apoptosis. 
Apoptosis, or programmed cell death, occurs as a cell’s defence for the development 
and health of multi cellular organisms. Due to a variety of stimuli that the cells might 
undergo, the cells become more “sensitive” such as they might die or go through 
apoptosis. This makes apoptosis distinct from another form of cell death called 
necrosis in which uncontrolled cell death leads to lysis of cells, inflammatory 
responses and, potentially, to serious health problems. 
Some factors like injuries, bacterial toxins or even nutrition deprivation can commit 
the cell to undergo through necrosis. Usually toxins that are secreted by bacteria may 
disrupt internal or external structure and functions in a result: the cell loses functional 
control, osmotic pressure causes swelling in organelles, the chromatin clumps and the 
cell eventually bursts. Cytotoxic cellular components spill out from the membrane 
inducing tissue damage and inflammation. 
Molecular signals continually inhibit or promote this process. Bcl-2 protein is an 
inhibitor of apoptosis which is located on the outer mitochondrial membrane. If Bcl-2 
gets deactivated then apoptosis is being initiated  through a well-controlled chain of 
enzymatic reactions. Catabolic processes begin throughout the cell. Enzymes digest 
cytosolic components and fragment the nuclear DNA. Specialized cysteine proteases 
called caspases, target specific proteins in the nuclear lamina and cytoskeleton. The 
cell is repackaged for safe removal. The chromatin condenses; the cell shrinks and 
fragments into small membrane-bound apoptotic bodies. Finally, the compacted cell is 
phagocytized by adjoining cells. Maintaining the proper number of cells in any tissue 
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requires a delicate balance between cellular production and elimination. Essential to 
this balance is apoptotic cell loss on one hand and cell division on the other. When an 
excess of cells is produced by unrestrained cell division, or when too few cells are 
eliminated by apoptosis, an excess of cells accumulates in the tissue. This basically 
describes the situation in cancer. Cells on their way to becoming cancerous 
accumulate a number of genetic and chromosomal abnormalities, each of which in 
some way pushes the cell further in the direction of unrestricted growth. At first, 
clusters of genetically identical cells are formed, each cell dividing with less restraint 
than its normal neighbours. Some viruses associated with cancers use tricks to prevent 
apoptosis of the cells they have transformed. Even cancer cells produced without the 
participation of viruses may have tricks to avoid apoptosis. High levels of apoptotic 
inhibitors follow when the BCL-2 gene, when it gets translocated into an enhancer 
region for antibody production. Some B-cell leukaemia and lymphomas express high 
levels of Bcl-2, thus blocking apoptotic signals they may receive. (R. A. Goldsby et 
al., 2000)
Is serotonin connected with Bcl-2?
In order to find if there is a connection between 
serotonin and Bcl-2 we first have to make clear what 
exactly serotonin and Bcl-2 are. Serotonin or else 5-
hydroxythryptamine (5-HT) is a monoamine 
neurotransmitter that is primarily located into the 
gastrointestinal tract, platelets and the central nervous 
system (CNS). It is widely known to be the main 
influence over several brain functions for example 
control of perception, cognition, sleep, appetite, pain, and mood.Serotonin uses 
specialized signaling pathways (interactions with receptors that are located in the 
CNS and PNS) to mediate biological functions. (Science Daily, 2010) As it was 
mentioned before BCL-2 is a proto-oncogene that is located on chromosome 18. As a 
result of DNA translation, BCL-2 gives an integral membrane protein (Bcl-2) that is 
located mainly in intracellular compartments.
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Illustration 2: Serotonin | 5-
hydroxythryptamine
High levels of the Bcl-2 protein protect B 
cells (such as lymphocytes) from early 
apoptotic death by preventing the 
activation of caspases that carry out 
apoptosis. Sometimes BCL-2 locus goes 
through a reciprocal translocation that 
gives rise to a malignant clone of B cells. 
That is the reason why this translocation 
can be found in B-cell leukemia and B-
cell lymphomas. (Kimball's Biology 
Pages, 2011)
As you can see in illustration 4, 
chromosome 18, containing the BCL-
2 locus, has undergone a reciprocal 
translocation with respect to chromosome 
14, this contains the antibody heavy chain 
locus. This t(14;18) translocation places 
the BCL-2 gene close to the heavy chain 
gene enhancer, which 
is very active in 
B-cells. => In 
t(14;18) cells,  Bcl-2 
protein is expressed 
at high levels cells.)
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Illustration 3: Schematic illustration of 5-HTP 
conversion to Serotonin and mechanism of 
SSRIs. 1: Tryptophan enters system. 2: Converts to 
5-HTP. 3: 5-HTP converts to 5-HT 4: 5-HT passes 
through membrane into synaptic cleft. 5: 5-HT 
stimulates it's receptor. 6: 5-HT joins with the 
reuptake transporter to cycle through again. 7: 
Reuptake inhibitors (such as Prozac) increase 5-HT 
level in synaptic cleft by inhibiting the reuptake of 
5-HT by the presynaptic neuron.
Illustration 4: Sister chromosomes and translocation of Bcl-3
There are two major categories of 
Bcl-2 proteins. Anti-apoptotic 
Bcl-2 proteins and Pro-apoptotic 
Bcl-2 proteins. The last have an 
important role in regulating 
apoptosis. Bcl-2 proteins control 
mitochondrial outer membrane 
permeabilizationn by activating 
the pro-apoptotic BCL-2 effector 
molecules, BAX and BAK 
(NCBI, 2000)(PNAS, 2008). 
Blood Cells 
In our bones we find the bone marrow, a soft substance responsible for the production 
of blood cells or stem cells, in their immature state. They will remain in the bone 
marrow till they become mature, being send to the blood vessels by then. We named it 
peripheral blood. Bone marrow produces different kind of blood cells: white blood 
cells who fight infections, red blood cells to carry oxygen by tissues throughout our 
body and platelets to control bleeding.
Different types of blood cancer
Table 1:
Blood Cancers Description Treatment
Leukaemia Affects Bone Marrow, destabilizes 
growth of white blood cells.
Chemotherapy, Immunotherapy, 
Radiation, Stem Cell Transplantation
Hodgkin’s 
Lymphoma
Affects lymph nodes, accelerates cell 
production
Radiation, Chemotherapy, Stem Cell 
Transplantation
Non-Hodgkin’s 
Lymphoma,
Burkitt's 
Lymphoma
Affects lymphatic system, destabilizes 
lymphocyte, B-cell, T-cell.
Monitor Surveillance / Observation, 
Chemotherapy, Immunotherapy, 
Radiation, Stem Cell Transplantation, 
Multiple Myeloma Affects the plasma/white cells, leading 
to a abnormal growth of these. 
Chemotherapy
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Illustration 5: Pro and Anti apoptotic proteins.
Cancer Treatments
Table 2:
Treatments Side effects 
Chemotherapy These depend on the type of pharmaceutical 
drugs and doses used. There is a higher chance 
of infection, hematomas or bleeding, tired and 
weak, loss of hair, a possibility in a colour 
change of the hair, nauseas and vomit, diarrhoea 
and wounds in the throat and mouth. 
Immunotherapy Depends on the type of substances and the effect 
on the patient. Usually there is a swallow around 
the injection wound and some patients may 
present flu symptoms. 
Radiation Weakness and tired, a permanent probability of 
skin colour change, hair loss, nausea and vomit, 
diarrhoea. 
Stem cells transplantation If the stem cells received from a donor are 
rejected, these stem cells will attack the system 
of the one receiving them, affecting the liver, 
skin or the digestive system. It can be a serious 
problem, even fatal. 
Monitoring Vigilance There is no side effects on this type of treatments 
as in Monitoring there isn’t much to be done 
then just waiting for the type of cancer to 
diminish by itself or the symptoms become more 
expressed. 
Surgery Surgery can end in a scar or if really unlucky, the 
operation can go wrong. But surgery is 
considered as a 100% treatment so side effects 
are non-existent, as in Monitoring vigilance. 
MDMA
It is known as a party drug, also called ecstasy or 
M, taken mostly orally as pills or crystals which 
makes you have a happy feeling and lose your 
inhibitions. Which can let you go on the whole 
night in a high gear (Erowid, 2011).
It has also in been used for therapy against post-
traumatic stress. It was created as a trial for 
antidepressants. MDMA is neurotoxic. It enters the 
axon terminals for serotonin, by the reuptake 
transporters, because MDMA has a bigger affinity 
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Illustration 6: 
MDMA | 3,4-Methylene-
dioxymethamphetamine
for the transporter than serotonin. Then it stimulates vesicles inside the axon to release 
a large amount of serotonin into the synapse. When such a large amount of serotonin 
is released into the synapse, it activates the serotonin transporters at the dendrite, 
which sends out the signal from the neurotransmitter to the rest of the brain and body.
After a while MDMA will have caused all serotonin be released, and the body makes 
new serotonin slowly, this will cause a down effect. Then the re-uptake transporters 
will be exposed and dopamine can get up the serotonin axon. When dopamine enters 
the axon, it will be degenerated by MAO (Monoamine oxidase) which will cause 
oxidative stress because the free radical hydrogenperoxide is released, this will over 
time destroy the axons cells.
Possibly MDMA also cause an increase in neural activity, which uses more ATP than 
the mitochondria can create, this leads to cell death. Some of the side effects from 
MDMA can be wide, confusion, sleep problems, depression, bigger anxiety to smaller 
side effects as muscle tension, nausea, blurred vision, chills and excessive sweating. 
The effect MDMA gives when you take it, gets less intense the more regular you take 
it. And if you take it on a regular basis, the side effects can escalate to lesser 
performance and affect the short term memory. High doses of MDMA can potentially 
lead to interfere with the body’s ability to regulate it’s temperature which can cause 
hypothermia. Even though you don’t get physical addicted to MDMA, you can still 
experience a form of withdrawal, fatigue, loss of appetite, depressive feelings and 
have trouble concentrating, if you stop using after a regular basis (thegooddrugsguide, 
2011).
Researches have shown that extension of the α-substituent of MDMA larger than an 
ethyl group, made the psycho activity no longer exist. A reaction was made of 
different nitriles and piperonylzinc phosphate, that gave a series of piperonyl ketones. 
Which should be α-substituents (the first carbon attaching the functional group). (J. 
Gordon, 2010)
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MDMA analogues
In research (J. Gordon et al., 
2010) is being noted that 
lymphoma cells are targets for 
neurotransmitters. The 
serotonin transporter and the 
dopamine transporter that are 
not only located on the brain 
cells but also they are located on the immune cells.
The fat in some of the blood cancer cell walls attracted MDMA, which then will cause 
serotonin to release in the cancer cells. The serotonin will stimulate the BCL-2 
protein, and activate caspases, which will lead the BL cells to go into apoptosis 
(Healthland, 2011). The lymphoma cells that are being studied by Gordon et al. derive 
from the immune cells called B-cells. B-cells 
make up to 80-90% of non- Hodgkin’s 
lymphoma cases. When MDMA analogues 
were modified, a less toxic dose could be a 
good anticancer strategy according to the 
research.
Researches have shown that extension of the 
α-substituent of MDMA, larger than an ethyl-
group, made the psych activity no longer 
existent. It was also found that attaching a 
phenyl-group increased potency against 
sensitive Bcl-2 deplete, Burkitt’s lymphoma cells 10-fold relative to MDMA. Also 
some related analogues were synthesized by containing 1-and 2-naphthyl and para-
biphemyl substituents although they were 100-fold more potent. As well it can be seen 
in illustration 8 (J. Gordon, 2010) that the analogues are hardly toxic to the cells, 
while MDMA seems to be toxic,  and is even noticeable at low doses.
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Illustration 7: MDMA and low neurotoxic analogues
Illustration 8: Neurotoxicity MDMA compared 
to analogue 11r & s on cells ((cell line) SH-
SY5Y)
Analysis
The treatments for cancer that exist nowadays have some heavy side effects that might 
be avoided by the research of a new treatment by using MDMA analogues. Of course, 
it cannot be available yet as the doses for this treatment remain unknown in order for 
the human body to resist the toxicity levels.  
Table 3:
Chemotherapy VS MDMA analogues
Chemotherapy side effects MDMA analogues side effects (Known 
till now.)
Higher chance of infection, hematomas or 
bleeding, tired and weak, loss of hair, a 
possibility in hair colour change, nauseas 
and vomit, diarrhoea and wounds in the 
throat and mouth. 
Doses to treatment success are too high to 
be applied to human patients. It can treat 
the cancer but it might kill the patient if 
the doses are too high in a result of 
increasing the toxicity levels in the body. 
So comparing these two treatments, the common drugs that are being used in 
Chemotherapy, nowadays to treat cancer, have many side effects. On the other hand, 
MDMA analogues' side effects might be much less, but it still is a substance under 
research. By our research, MDMA analogues can be a possible ”candidate” for cancer 
treatment but in a few decades away.
Discussion
The treatments for cancer that exist nowadays have some heavy side effects that might 
be avoided by the research of a new treatment by using MDMA analogues. 
There might even not be a side effect by using MDMA analogues. But first of all 
more tests needs to be made, to get an analogue which is not neurotoxic or causes 
psychoactivity but cytotoxic enough to cause the BL-cells to go into apoptosis and 
thereby kill the cancer.
The study leads in a direction of a better cancer treatment, with no heavy side effects, 
which also has the possibility of a much larger treatment rate.
For now the most successful tests has been on Burkitt’s lymphoma, but the MDMA 
analogue has possibilities on most blood cancers, so there might be analogues that 
could be a better treatment for Leukaemia.
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Conclusion
The studies gave us a link between MDMA and cancer. As for how it can be used as a 
treatment for cancer. The scientific studies showed that analogues which nearly ruled 
out psychoactivity could be made.
Those analogues that nearly ruled out psychoactivity did also increase toxicity 
towards killing the cancer cells. But there is still needed a larger amount of the 
analogue to kill the cancer cell, which results in the analogue still being neurotoxic.
A more cytotoxic and less neurotoxic analogue, would be a promising new substitute 
for chemotherapy in cancer treatment. The side effects will be fewer than with 
chemotherapy, because the cancer cell attracts the MDMA. That makes MDMA more 
specific, which will rule out the same side effects that chemotherapy has, like cell 
death of nearby and fast dividing cells, which for example can cause hair loss.
Perspective
Further research should be done, to reach a more conclusive answer to whether 
MDMA-analogues can be applicable in cancer treatments. There is a long way to go, 
but it seems there a good possibilities. The analogues do kill cancer cells in the lab, so 
next steps could include research in small mammals, primates, and eventually clinical 
tests on humans, but that is a thing far off for now.
With further research, MDMA analogues might be a good substitute for chemotherapy 
for selected blood cancers.
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